Adverse Drug Events Related to Common Asthma Medications in US Hospitalized Children, 2000–2016

Luyu Xie, Andrew Gelfand, Matthew S. Mathew, Folefac D. Atem, Nimisha Srikanth, George L. Delclos, Sarah E. Messiah

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The reduction in adverse drug events is a priority in healthcare. Medications are frequently prescribed for asthmatic children, but epidemiological trends of adverse drug events related to anti-asthmatic medications have not been described in hospitalized children. Objective: The objective of this study was to report incidence trends, risk factors, and healthcare utilization of adverse drug events related to anti-asthmatic medications by major drug classes in hospitalized children in the USA from 2000 to 2016. Methods: A population-based temporal analysis included those aged 0–20 years who were hospitalized with asthma from the 2000 to 2016 Kids Inpatient Database. Age-stratified weighted temporal trends of the inpatient incidence of adverse drug events related to anti-asthmatic medications (i.e., corticosteroids and bronchodilators) were estimated. Stepwise multivariate logistic regression models generated risk factors for adverse drug events. Results: From 2000 to 2016, 12,640 out of 698,501 pediatric asthma discharges (1.7%) were associated with adverse drug events from anti-asthmatic medications. 0.83% were adverse drug events from corticosteroids, resulting in a 1.14-fold increase in the length of stay (days) and a 1.42-fold increase in hospitalization charges (dollars). The overall incidence (per 1000 discharges) of anti-asthmatic medication adverse drug events increased from 5.3 (95% confidence interval [CI] 4.6–6.1) in 2000 to 21.6 (95% CI 18.7–24.6) in 2016 (p-trend = 0.024). Children aged 0–4 years had the most dramatic increase in the incidence of bronchodilator adverse drug events from 0.2 (95% CI 0.1–0.4) to 19.3 (95% CI 15.2–23.4) [p-trend ≤ 0.001]. In general, discharges among asthmatic children with some comorbidities were associated with an approximately two to five times higher odds of adverse drug events. Conclusions: The incidence of adverse drug events from common anti-asthmatic medications quadrupled over the past decade, particularly among preschool-age children who used bronchodilators, resulting in substantial increased healthcare costs. Those asthmatic children with complex medical conditions may benefit the most from adverse drug event monitoring.

Original languageEnglish (US)
JournalDrugs - Real World Outcomes
DOIs
StateAccepted/In press - 2022

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Adverse Drug Events Related to Common Asthma Medications in US Hospitalized Children, 2000–2016'. Together they form a unique fingerprint.

Cite this